“Efficiency integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer and an activating EGFR gene mutation”., Вопр. онкол., vol. 67, no. 2, pp. 246–253, May 2022, doi: 10.37469/0507-3758-2021-67-2-246-253.